37 Randomized controlled trial comparing botulinum versus surgery for drooling in neurodisabilities 2 REFERENCES 1. Blasco PA, Allaire JH. Drooling in the developmentally disabled: management practices and recommendations. Consortium on Drooling. Dev Med Child Neurol 1992; 34: 849–62. 2. Speyer R, Cordier R, Kim JH, Cocks N, Michou E, Wilkes-Gillan S. Prevalence of drooling, swallowing, and feeding problems in cerebral palsy across the lifespan: a systematic review and meta-analyses. Dev Med Child Neurol 2019; 61: 1249–58. 3. Brody GS. Control of drooling by translocation of parotid duct and extirpation of mandibular gland. Dev Med Child Neurol 1977; 19: 514–7. 4. Bekkers S, Delsing CP, Kok SE, et al. Randomized controlled trial comparing botulinum vs surgery for drooling in neurodisabilities. Neurology 2019; 92: e1195–e204. 5. Bekkers S, Pruijn IMJ, Van Hulst K, et al. Submandibular duct ligation after botulinum neurotoxin A treatment of drooling in children with cerebral palsy. Dev Med Child Neurol 2020; 62: 861–7. 6. Jongerius PH, van den Hoogen FJ, van Limbeek J, Gabreels FJ, van Hulst K, Rotteveel JJ. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 2004; 114: 620–7. 7. Bekkers S, van Ulsen KJ, Adang EMM, Scheffer ART, van den Hoogen FJA. Cost-effectiveness of botulinum neurotoxin A versus surgery for drooling: a randomized clinical trial. Dev Med Child Neurol 2020; 62: 1302–8. 8. Schroeder AS, Kling T, Huss K, et al. Botulinum toxin type A and B for the reduction of hypersalivation in children with neurological disorders: a focus on effectiveness and therapy adherence. Neuropediatrics 2012; 43: 27–36. 9. Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology 2019; 92: e48–e54. 10. Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs 2012; 26: e1–9. 11. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004; 19(Suppl. 8): S92–S100. 12. Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 2009; 32: 213–8. 13. Erasmus CE, van Hulst K, Scheffer AR, et al. What could predict effectiveness of botulinum toxin to treat drooling: a search for evidence of discriminatory factors on the level of body functions or structures. Eur J Paediatr Neurol 2012; 16: 126–31. 14. Sreebny LM. Saliva in health and disease: an appraisal and update. Int Dent J 2000; 50: 140–61. 15. Bekkers S, van Hulst K, Erasmus CE, Delsing CP, Scheffer ART, van den Hoogen FJA. An evaluation of predictors for success of two-duct ligation for drooling in neurodisabilities. J Neurol 2020; 267: 1508–15. 16. Delsing CPA, Bekkers S, van Hulst K, Erasmus CE, van den Hoogen FJA. Unsuccessful submandibular duct surgery for anterior drooling: Surgical failure or parotid gland salivation? Int J Pediatr Otorhinolaryngol 2019; 123: 132–7. 17. van Hulst K, Lindeboom R, van der Burg J, Jongerius P. Accurate assessment of drooling severity with the 5-minute drooling quotient in children with developmental disabilities. Dev Med Child Neurol 2012; 54: 1121–6.
RkJQdWJsaXNoZXIy MjY0ODMw